Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2020

Multiple Myeloma

View all
4:10
KarMMa: idecabtagene vicleucel QoL
Michel Delforge • 15 Jun 2020
1:17
Impact of prior therapies on efficacy of belantamab mafodotin in R/R myeloma
Sagar Lonial • 19 Jun 2020
4:30
IKEMA: kD vs isatuximab and kD in R/R myeloma
Philippe Moreau • 16 Jun 2020
7:57
Updates on DREAMM-6 and DREAMM-2 in R/R myeloma
Rakesh Popat • 12 Jun 2020

CLL

View all
4:13
Front-line and R/R updates in CLL from EHA
Peter Hillmen • 17 Jun 2020
5:54
Updates from CAPTIVATE: ibrutinib and venetoclax for CLL
Tanya Siddiqi • 17 Jun 2020
4:30
CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil
Othman Al-Sawaf • 14 Jun 2020
3:15
Umbralisib with ibrutinib in patients with R/R CLL or MCL
Matthew Davids • 11 Jun 2020

Lymphoma

View all
5:39
Acalabrutinib monotherapy in mature B-cell malignancies
Richard Furman • 10 Jun 2020
2:16
ALEXANDER: bicistronic CD19 & CD22 CAR for DLBCL
Wendy Osborne • 1 Jun 2020
4:07
HD17: PET guided omission of radiotherapy in Hodgkin lymphoma
Peter Borchmann • 3 Jun 2020
10:56
Liso-cel for second-line R/R aggressive large B-cell NHL
Nilanjan Ghosh • 18 Jun 2020

MDS

View all
2:05
Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti • 2 Jun 2020
6:51
Anti-TIM-3 antibody sabatolimab + hypomethylating agents for high-risk MDS & AML
Uma Borate • 8 Jun 2020

ALL

View all
5:46
The role of the gut microbiome in protecting genetically predisposed mice against leukemia
Carolina Vicente-Dueñas • 28 May 2020
4:03
FORUM: total body irradiation vs chemotherapy in pediatric ALL
Christina Peters • 11 Jun 2020

AML

View all
2:05
Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti • 2 Jun 2020
2:16
Rationale for 10-day decitabine with venetoclax for high-risk AML
Abhishek Maiti • 1 Jun 2020
6:21
Decitabine and venetoclax for AML
Abhishek Maiti • 1 Jun 2020
9:17
Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness
Abhishek Maiti • 2 Jun 2020

MPNs

View all
3:39
Efficacy of navitoclax with ruxolitinib in myelofibrosis patients
Claire Harrison • 5 Jun 2020
1:53
Parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
Abdulraheem Yacoub • 12 Jun 2020
3:49
Second primary malignancy after treatment with ruxolitinib
Francesca Palandri • 16 Jun 2020
1:24
Imetelstat in high-risk triple-negative myelofibrosis
Jean-Jacques Kiladjian • 15 Jun 2020

Immuno-Oncology

View all
4:23
LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCL
Charles Herbaux • 10 Jun 2020
3:52
Myeloma: immunotherapy updates from EHA 2020
Mohamad Mohty • 9 Jun 2020
6:01
CD19 CAR-T for lymphoma: real-world experience in the UK
Andrea Kuhnl • 14 Jun 2020
2:16
ALEXANDER: bicistronic CD19 & CD22 CAR for DLBCL
Wendy Osborne • 1 Jun 2020

COVID-19 & Hematological Malignancy

View all
2:23
John Gribben talks on Coronavirus
John Gribben • 27 Apr 2020
4:00
Positive learnings in myeloma management to come out of COVID-19 pandemic
Mohamad Mohty • 9 Jun 2020
2:00
Impact of COVID-19 on treatment of B-cell malignancies
Arnon Kater • 8 Jun 2020
2:56
Managing lymphoma during the COVID-19 pandemic
Peter Borchmann • 3 Jun 2020
The content of VJHemOnc is intended for healthcare professionals